Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

KalVista Pharmaceuticals

Nasdaq:KALV
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
KALV
Nasdaq
$130M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The last earnings update was 18 days ago. More info.


Add to Portfolio Compare Print
  • KalVista Pharmaceuticals has significant price volatility in the past 3 months.
KALV Share Price and Events
7 Day Returns
6.3%
NasdaqGM:KALV
6.3%
US Biotechs
12.6%
US Market
1 Year Returns
-74.6%
NasdaqGM:KALV
1.6%
US Biotechs
-9.1%
US Market
KALV Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
KalVista Pharmaceuticals (KALV) 6.3% -45.6% -55.6% -74.6% -6.8% -
US Biotechs 6.3% -7.9% -7.9% 1.6% 7.7% -8.8%
US Market 12.6% -16.7% -19.6% -9.1% 8.2% 21.5%
1 Year Return vs Industry and Market
  • KALV underperformed the Biotechs industry which returned 1.6% over the past year.
  • KALV underperformed the Market in United States of America which returned -9.1% over the past year.
Price Volatility
KALV
Industry
5yr Volatility vs Market
Related Companies

Value

 Is KalVista Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for KalVista Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is $7.28.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for KalVista Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are KalVista Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:KALV PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2020-01-31) in USD $-1.77
NasdaqGM:KALV Share Price ** NasdaqGM (2020-03-27) in USD $7.28
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.87x
United States of America Market PE Ratio Median Figure of 2,935 Publicly-Listed Companies 13.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of KalVista Pharmaceuticals.

NasdaqGM:KALV PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:KALV Share Price ÷ EPS (both in USD)

= 7.28 ÷ -1.77

-4.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • KalVista Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.
  • KalVista Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does KalVista Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGM:KALV PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.12x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
39.1%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.99x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1.03x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for KalVista Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on KalVista Pharmaceuticals's assets?
Raw Data
NasdaqGM:KALV PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2020-01-31) in USD $5.03
NasdaqGM:KALV Share Price * NasdaqGM (2020-03-27) in USD $7.28
United States of America Biotechs Industry PB Ratio Median Figure of 428 Publicly-Listed Biotechs Companies 2.47x
United States of America Market PB Ratio Median Figure of 5,145 Publicly-Listed Companies 1.27x
NasdaqGM:KALV PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:KALV Share Price ÷ Book Value per Share (both in USD)

= 7.28 ÷ 5.03

1.45x

* Primary Listing of KalVista Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • KalVista Pharmaceuticals is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess KalVista Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. KalVista Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is KalVista Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
39.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is KalVista Pharmaceuticals expected to grow at an attractive rate?
  • KalVista Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • KalVista Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • KalVista Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:KALV Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:KALV Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts 39.1%
NasdaqGM:KALV Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 65.6%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:KALV Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:KALV Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-04-30 163 -37 52 2
2023-04-30 76 -86 -15 2
2022-04-30 24 -91 -55 2
2021-04-30 5 -58 -61 6
2020-04-30 11 -47 -35 6
2020-03-28
NasdaqGM:KALV Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2020-01-31 12 -43 -31
2019-10-31 14 -40 -26
2019-07-31 16 -41 -23
2019-04-30 16 -36 -21
2019-01-31 18 -32 -13
2018-10-31 16 7 -14
2018-07-31 12 9 -16
2018-04-30 8 11 -16
2018-01-31 4 14 -19
2017-10-31 2 -26 -22
2017-07-31 1 -23 -21
2017-04-30 2 -24 -21

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • KalVista Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • KalVista Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:KALV Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from KalVista Pharmaceuticals Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:KALV Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-04-30 2.08 2.92 1.24 2.00
2023-04-30 -0.77 0.09 -1.62 2.00
2022-04-30 -2.59 -2.31 -2.87 2.00
2021-04-30 -2.82 -2.38 -3.52 7.00
2020-04-30 -1.94 -1.81 -2.11 6.00
2020-03-28
NasdaqGM:KALV Past Financials Data
Date (Data in USD Millions) EPS *
2020-01-31 -1.77
2019-10-31 -1.48
2019-07-31 -1.38
2019-04-30 -1.38
2019-01-31 -0.96
2018-10-31 -1.20
2018-07-31 -1.50
2018-04-30 -1.53
2018-01-31 -1.93
2017-10-31 -2.38
2017-07-31 -3.07
2017-04-30 -4.47

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if KalVista Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess KalVista Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
KalVista Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has KalVista Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare KalVista Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • KalVista Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare KalVista Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare KalVista Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
KalVista Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from KalVista Pharmaceuticals Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:KALV Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2020-01-31 11.79 -31.06 12.78
2019-10-31 14.11 -25.72 12.61
2019-07-31 15.78 -23.12 11.80
2019-04-30 16.13 -20.82 10.93
2019-01-31 18.04 -12.95 9.84
2018-10-31 16.48 -14.23 9.07
2018-07-31 12.02 -15.91 9.16
2018-04-30 8.39 -15.81 8.86
2018-01-31 3.67 -19.35 2.71
2017-10-31 1.59 -21.95 5.61
2017-07-31 0.63 -21.23 4.15
2017-04-30 1.50 -20.78 11.18
2017-01-31 1.67 -22.80 10.10
2016-10-31 1.77 -18.04 5.61
2016-07-31 2.27 -17.51 4.97
2016-04-30 2.13 -15.48 2.65
2015-04-30 1.80 -9.20 1.61

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if KalVista Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if KalVista Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if KalVista Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess KalVista Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
KalVista Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is KalVista Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up KalVista Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • KalVista Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • KalVista Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of KalVista Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • KalVista Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from KalVista Pharmaceuticals Company Filings, last reported 1 month ago.

NasdaqGM:KALV Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2020-01-31 89.75 0.00 80.57
2019-10-31 97.79 0.00 93.46
2019-07-31 101.87 0.00 100.37
2019-04-30 96.74 0.00 100.81
2019-01-31 104.03 0.00 111.15
2018-10-31 106.95 0.00 121.12
2018-07-31 26.25 0.00 48.07
2018-04-30 27.25 0.00 51.06
2018-01-31 28.57 0.00 58.68
2017-10-31 31.08 0.00 28.13
2017-07-31 26.73 0.00 26.46
2017-04-30 31.33 0.00 30.95
2017-01-31 34.85 0.00 33.50
2016-10-31 11.84 0.00 10.68
2016-07-31 16.21 0.00 15.63
2016-04-30 21.50 0.00 21.76
2015-04-30 2.05 0.00 2.53
  • KalVista Pharmaceuticals has no debt.
  • KalVista Pharmaceuticals has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • KalVista Pharmaceuticals has sufficient cash runway for 1.9 years based on current free cash flow.
  • KalVista Pharmaceuticals has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 25.2% each year.
X
Financial health checks
We assess KalVista Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. KalVista Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is KalVista Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from KalVista Pharmaceuticals dividends.
If you bought $2,000 of KalVista Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate KalVista Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate KalVista Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:KALV Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:KALV Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-04-30
2023-04-30
2022-04-30
2021-04-30
2020-04-30
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as KalVista Pharmaceuticals has not reported any payouts.
  • Unable to verify if KalVista Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of KalVista Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as KalVista Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess KalVista Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can KalVista Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. KalVista Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of KalVista Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Andy Crockett
COMPENSATION $3,287,944
AGE 44
TENURE AS CEO 3.3 years
CEO Bio

Mr. Thomas Andrew Crockett, also known as Andy, M.B.A., has been Chief Executive Officer and Director of KalVista Pharmaceuticals, Inc. since November 21, 2016. Mr. Crockett is the Founder of KalVista Pharmaceuticals Ltd. and also served as its Chief Executive Officer. Mr. Crockett has been the Chief Executive Officer of Vantia Ltd. since June 2010. He served as Vice President of business development of Vantia Ltd. from 2009 to June 2010. Mr. Crockett served as Vice President of Business Development of ZARS Pharma, Inc. since June 2005. Mr. Crockett served as Director of S-Caine Projects and Business Development of ZARS Pharma, Inc. Mr. Crockett joined Zars in August 1999. He held various senior management positions including chief executive, vice president of business development and director or clinical and regulatory affairs in biotech and specialty pharmaceutical companies in the United States and United Kingdom. During his career he has identified, negotiated and executed strategic corporate transactions on a global basis, including merger and acquisitions, national and international product licences, IP and technology licences and R&D alliances. He worked in the engineering department and managed the manufacturing activities at Microject, a drug delivery technology company, from June 1997 to June 1999. He served as a Director at KalVista Pharmaceuticals Ltd. He serves as a Director of Vantia Ltd. Mr. Crockett holds a B.A. from the University of Utah. Mr. Crockett has studied at Harvard Business School and also holds an MBA from The Wharton School, University of Pennsylvania, with a major in finance.

CEO Compensation
  • Andy's compensation has increased whilst company is loss making.
  • Andy's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the KalVista Pharmaceuticals management team in years:

3.3
Average Tenure
54
Average Age
  • The tenure for the KalVista Pharmaceuticals management team is about average.
Management Team

Andy Crockett

TITLE
CEO & Director
COMPENSATION
$3M
AGE
44
TENURE
3.3 yrs

Ben Palleiko

TITLE
Chief Business Officer & CFO
COMPENSATION
$2M
AGE
53
TENURE
3.6 yrs

Ed Feener

TITLE
Chief Scientific Officer
COMPENSATION
$2M
AGE
59
TENURE
3.3 yrs

Leah Monteiro

TITLE
Director of Corporate Communications & Investor Relations

Rachel Morten

TITLE
Head of Regulatory Affairs and QA

Chris Yea

TITLE
Chief Development Officer
AGE
55
TENURE
3.3 yrs

Andreas Maetzel

TITLE
Senior Vice President of Medical
COMPENSATION
$417K
AGE
56
TENURE
3 yrs

Michael Smith

TITLE
Senior Vice President of Development
TENURE
0.3 yrs

Stephen Donnelly

TITLE
Director of Finance and Company Secretary

John McKune

TITLE
Vice President of Finance
COMPENSATION
$516K
AGE
43
Board of Directors Tenure

Average tenure and age of the KalVista Pharmaceuticals board of directors in years:

3.3
Average Tenure
61.5
Average Age
  • The tenure for the KalVista Pharmaceuticals board of directors is about average.
Board of Directors

Martin Edwards

TITLE
Former Director
AGE
63
TENURE
0.8 yrs

Andy Crockett

TITLE
CEO & Director
COMPENSATION
$3M
AGE
44
TENURE
3.3 yrs

Ed Unkart

TITLE
Director
COMPENSATION
$165K
AGE
69
TENURE
3.3 yrs

Albert Cha

TITLE
Director
COMPENSATION
$166K
AGE
47
TENURE
3.3 yrs

Tomas Kiselak

TITLE
Board Observer
TENURE
4.7 yrs

Bong Koh

TITLE
Board Observer
AGE
46
TENURE
4.7 yrs

Arnie Oronsky

TITLE
Director
COMPENSATION
$165K
AGE
80
TENURE
3.3 yrs

Brian J. Pereira

TITLE
Director
COMPENSATION
$191K
AGE
60
TENURE
1.1 yrs

Dan Soland

TITLE
Director
COMPENSATION
$265K
AGE
63
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
30. Sep 19 Buy Daniel Soland Individual 26. Sep 19 27. Sep 19 10,000 $11.90 $118,750
19. Jul 19 Buy Vivo Capital, LLC Company 17. Jul 19 19. Jul 19 61,280 $17.84 $1,090,296
30. Jul 19 Buy Vivo Capital, LLC Company 26. Jul 19 29. Jul 19 56,367 $17.13 $957,737
24. Apr 19 Sell RA Capital Management, L.P. Company 22. Apr 19 23. Apr 19 -172,300 $25.95 $-4,469,503
15. Apr 19 Buy RA Capital Management, L.P. Company 05. Apr 19 11. Apr 19 482,500 $29.56 $13,599,769
10. Apr 19 Sell SV Health Investors, LLC Company 08. Apr 19 10. Apr 19 -50,000 $29.49 $-1,460,145
02. Apr 19 Sell SV Health Investors, LLC Company 29. Mar 19 02. Apr 19 -97,074 $28.76 $-2,720,897
X
Management checks
We assess KalVista Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. KalVista Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Investors Who Bought KalVista Pharmaceuticals (NASDAQ:KALV) Shares A Year Ago Are Now Up 156%

Check out our latest analysis for KalVista Pharmaceuticals KalVista Pharmaceuticals isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … KalVista Pharmaceuticals grew its revenue by 392% last year. … A Different Perspective KalVista Pharmaceuticals boasts a total shareholder return of 156% for the last year.

Simply Wall St -

The KalVista Pharmaceuticals (NASDAQ:KALV) Share Price Has Gained 156%, So Why Not Pay It Some Attention?

It hasn't been the best quarter for KalVista Pharmaceuticals, Inc. … Check out our latest analysis for KalVista Pharmaceuticals Because KalVista Pharmaceuticals is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … In the last year KalVista Pharmaceuticals saw its revenue grow by 392%.

Simply Wall St -

What Kind Of Shareholders Own KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)?

Every investor in KalVista Pharmaceuticals, Inc. … Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … KalVista Pharmaceuticals is a smaller company with a market capitalization of US$508m, so it may still be flying under the radar of many institutional investors.

Simply Wall St -

What Kind Of Investor Owns Most Of KalVista Pharmaceuticals Inc (NASDAQ:KALV)?

Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … KalVista Pharmaceuticals is a smaller company with a market capitalization of US$342m, so it may still be flying under the radar of many institutional investors. … institutions own shares in the company.

Simply Wall St -

What Does KalVista Pharmaceuticals Inc's (NASDAQ:KALV) Ownership Structure Look Like?

In this analysis, my focus will be on developing a perspective on KalVista Pharmaceuticals Inc’s (NASDAQ:KALV) latest ownership structure, a less discussed, but important factor. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … View out our latest analysis for KalVista Pharmaceuticals

Simply Wall St -

Does KalVista Pharmaceuticals Inc's (NASDAQ:KALV) Latest Financial Perfomance Look Strong?

After looking at KalVista Pharmaceuticals Inc's (NASDAQ:KALV) latest earnings announcement (31 January 2018), I found it useful to revisit the company's performance in the past couple of years and assess this against the most recent figures. … See our latest analysis for KalVista Pharmaceuticals Did KALV's recent earnings growth beat the long-term trend and the industry? … NasdaqGM:KALV Income Statement May 23rd 18 We can further assess KalVista Pharmaceuticals's loss by looking at what the industry has been experiencing over the past few years.

Simply Wall St -

Does KalVista Pharmaceuticals Inc's (KALV) Past Performance Indicate A Weaker Future?

After looking at KalVista Pharmaceuticals Inc's (NASDAQ:KALV) latest earnings update (31 July 2017), I found it helpful to revisit the company's performance in the past couple of years and compare this against the latest numbers. … Check out our latest analysis for KalVista Pharmaceuticals How Did KALV's Recent Performance Stack Up Against Its Past? … I prefer to use data from the most recent 12 months, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data.

Simply Wall St -

Should Your Next Investment In The Healthcare Industry Be In KalVista Pharmaceuticals Inc (KALV)?

This rate is larger than the growth rate of the US stock market as a whole. … In the previous year, the industry saw growth of 8.45%, though still underperforming the wider US stock market. … NasdaqGM:KALV PE PEG Gauge Nov 18th 17 The biotech industry is trading at a PE ratio of 27x, above the broader US stock market PE of 22x.

Simply Wall St -

Is KalVista Pharmaceuticals Inc's (KALV) Balance Sheet Strong Enough To Weather A Storm?

Check out our latest analysis for KalVista Pharmaceuticals Does KALV generate an acceptable amount of cash through operations? … We can test the impact of these adverse events by looking at whether cash from its current operations can pay back its current debt obligations. … As cash flow from operation is hindered by adverse events, KALV may need to liquidate its short-term assets to meet these upcoming payments.

Simply Wall St -

Company Info

Description

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE; and KVD824, an oral plasma kallikrein inhibitor that is in Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.

Details
Name: KalVista Pharmaceuticals, Inc.
KALV
Exchange: NasdaqGM
Founded:
$129,915,960
17,845,599
Website: http://www.kalvista.com
Address: KalVista Pharmaceuticals, Inc.
55 Cambridge Parkway,
Suite 901 East,
Cambridge,
Massachusetts, 02142,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM KALV New Ordinary Shares Nasdaq Global Market US USD 23. Nov 2016
DB 4XC1 New Ordinary Shares Deutsche Boerse AG DE EUR 23. Nov 2016
Number of employees
Current staff
Staff numbers
45
KalVista Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 02:53
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/23
Last earnings filing: 2020/03/10
Last earnings reported: 2020/01/31
Last annual earnings reported: 2019/04/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.